Neonc Technologies (NASDAQ:NTHI) President Amir Heshmatpour Acquires 10,000 Shares

Neonc Technologies Holdings, Inc. (NASDAQ:NTHI) President Amir Heshmatpour purchased 10,000 shares of the business’s stock in a transaction on Friday, May 1st. The shares were bought at an average price of $4.16 per share, with a total value of $41,600.00. Following the purchase, the president directly owned 3,072,000 shares in the company, valued at approximately $12,779,520. The trade was a 0.33% increase in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.

Neonc Technologies Price Performance

NTHI stock traded up $0.06 during mid-day trading on Monday, reaching $4.12. 27,958 shares of the company traded hands, compared to its average volume of 55,675. Neonc Technologies Holdings, Inc. has a fifty-two week low of $3.20 and a fifty-two week high of $12.99. The firm’s 50 day moving average price is $7.20 and its 200 day moving average price is $8.44.

Hedge Funds Weigh In On Neonc Technologies

Hedge funds and other institutional investors have recently modified their holdings of the business. Barclays PLC boosted its stake in shares of Neonc Technologies by 5,314.8% in the 4th quarter. Barclays PLC now owns 9,151 shares of the company’s stock worth $76,000 after buying an additional 8,982 shares during the last quarter. Foundations Investment Advisors LLC purchased a new position in shares of Neonc Technologies in the 3rd quarter worth approximately $100,000. SLT Holdings LLC purchased a new position in shares of Neonc Technologies in the 3rd quarter worth approximately $100,000. Goldman Sachs Group Inc. purchased a new position in shares of Neonc Technologies in the 4th quarter worth approximately $124,000. Finally, OMERS ADMINISTRATION Corp purchased a new position in shares of Neonc Technologies in the 4th quarter worth approximately $126,000.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on the company. Zacks Research upgraded Neonc Technologies to a “hold” rating in a research note on Wednesday, January 14th. BTIG Research assumed coverage on Neonc Technologies in a research note on Friday, April 24th. They set a “buy” rating and a $15.00 price target for the company. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Neonc Technologies in a research note on Friday, March 27th. One investment analyst has rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $15.00.

Neonc Technologies Company Profile

Neonc Technologies Holdings, Inc develops novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. Its lead products in development include NEO100, which is in Phase 2a clinical trials for treating glioblastoma; and NEO212, a covalently conjugated molecule combining the chemotherapeutic drug temozolomide with perillyl alcohol that is completed preclinical testing. The company was incorporated in 2023 and is based in Los Angeles, California.